Mercury Laboratories Reports 53.82% Profit Rise in FY26, Recommends Dividend

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorAnanya Iyer|Published at:
Mercury Laboratories Reports 53.82% Profit Rise in FY26, Recommends Dividend
Overview

Mercury Laboratories reported a 53.82% jump in net profit for FY26, reaching ₹4.83 crore. Revenue grew 1.11% to ₹75.94 crore. The company recommended a dividend of ₹3.50 per share, and received an unmodified auditor opinion. An exceptional loss of ₹0.39 crore was noted due to gratuity and leave liability provisions.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Mercury Laboratories Posts Strong FY26 Profit Growth, Recommends Dividend

Net Profit (FY26): ₹4.83 crore
Revenue (FY26): ₹75.94 crore

Reader Takeaway: Strong profit growth and dividend payout offset by provisions for new labour codes.

What just happened

Mercury Laboratories announced its audited financial results for the fiscal year ended March 31, 2026. The company reported a net profit after tax of ₹4.83 crore, a significant increase of 53.82% compared to ₹3.14 crore in the previous fiscal year. Revenue from operations saw a modest increase of 1.11% to ₹75.94 crore from ₹75.10 crore in FY25. Profit Before Tax grew by 42.49% to ₹6.64 crore. Earnings Per Share (EPS) rose to ₹40.28 from ₹26.21.

Why this matters

The substantial profit growth indicates improved operational efficiency and profitability for Mercury Laboratories. The recommendation of a dividend of ₹3.50 per share provides a direct financial return to its shareholders. An unmodified auditor opinion suggests confidence in the company's financial reporting.

The backstory

The company's financial performance has shown a positive trajectory. In FY25, the net profit stood at ₹3.14 crore. The current year's results mark a strong rebound and growth.

What changes now

Shareholders will receive a final dividend of ₹3.50 per share, subject to approval at the Annual General Meeting. The company will need to manage the implications of the new Labour Codes which led to an exceptional provision.

Risks to watch

An exceptional item loss of ₹0.39 crore was recorded due to additional provisions for gratuity and leave liability following the notification of final Central Rules on new Labour Codes. Future impacts from these regulations and their state-level implementation need monitoring.

Peer comparison

While specific peer performance for FY26 isn't detailed in the filing, the company's profit growth of over 50% appears robust. Investors may compare this against other pharmaceutical companies operating in a similar segment.

Context metrics (time-bound)

  • Revenue (FY26): ₹75.94 crore (up 1.11% from FY25)
  • Net Profit (FY26): ₹4.83 crore (up 53.82% from FY25)
  • EPS (FY26): ₹40.28 (up 53.68% from FY25)
  • Dividend Recommended: ₹3.50 per share
  • Exceptional Item Loss: ₹0.39 crore

What to track next

Investors should closely watch the company's performance in the upcoming quarters, particularly its ability to sustain profitability and manage the impact of the new Labour Codes as state-level rules are implemented.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.